Radiation plus chemo-immunotherapy for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with stage IV esophageal cancer that has spread to other parts of the body.
- You must be able to carry out daily activities with little or no help (ECOG 0 or 1).
- You must not have received any previous cancer treatment for esophageal cancer.
- You must have adequate organ function (bone marrow, kidneys, liver, heart) to safely receive chemotherapy and immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial studies whether adding an anti-PD-1 immunotherapy (with chemotherapy) together with radiation can help people with advanced esophageal squamous cell cancer. It’s for cases where surgery or standard definitive chemoradiation can’t be done, or the cancer has spread to distant sites.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial compares two approaches for people with esophageal cancer that has shrunk or disappeared after initial chemotherapy combined with immunotherapy. It looks at whether adding targeted radiation (DCRT) or surgery is better. The goal is to find the most effective next step for eligible patients.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
This trial combines a special high-dose radiation (SBRT) with immunotherapy to treat esophageal cancer that has spread to a few spots in the body (up to 5 spots in up to 3 organs). The goal is to see if this approach can better control the cancer.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.